Haleon (HLN) Earnings Date & Reports

Key Takeaways

• Haleon reported Q3 2026 organic revenue growth of +2.6%, below its own expectations, with reported revenue of £2.868 billion.
• Full-year 2026 organic revenue guidance was trimmed to around 2.5%, down from a previous 3%–5% range.
• Oral Health remained a bright spot, rising +8.8%, while Respiratory Health declined 2.0% on weak cold and flu consumption.
• A raw material classification change for Centrum over-the-counter (OTC) products in China weighed on performance, with no near-term resolution expected.
• The company announced an additional £500 million share buyback, while reaffirming high-single-digit adjusted operating profit growth at constant currency.
• For more on Haleon's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated HLN pages.
• Discover additional trade ideas and market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

Haleon's quarterly trading statement carries outsized weight because the consumer healthcare giant has spent recent quarters trying to restore consistent volume growth while defending margins. After posting 3.1% organic growth in Q2 2026 and reaffirming its medium-term ambition of 4%–6% growth, the company entered Q3 expecting stronger momentum across North America and emerging markets. Instead, softer cold and flu consumption and a regulatory classification shift in China disrupted that trajectory. For investors, the report tests whether management's turnaround strategy can deliver against a backdrop of uneven category demand, and whether the company's long-term growth guidance remains credible.

Reported Results

For the third quarter of its 2026 fiscal year, Haleon reported organic revenue growth of 2.6%, driven by +2.1% price and +0.5% volume/mix. Reported revenue rose 2.5% to £2.868 billion. By region, North America grew 2.5% organically to £992 million, APAC (Asia-Pacific) rose 3.9% to £593 million, and International markets climbed 6.9% to £485 million. Europe declined 0.6% to £798 million as a challenging consumer backdrop persisted.

Oral Health was the standout category, up 8.8%, while Respiratory Health fell 2.0% to £499 million amid subdued cold and flu demand. Management also cited a raw material classification change for Centrum OTC (over-the-counter) products in China as a headwind, noting no short-term fix was expected. As a result, full-year organic revenue growth guidance was lowered to around 2.5%, from a prior 3%–5%, while the company kept its high-single-digit adjusted operating profit growth outlook at constant currency and announced a further £500 million share buyback.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those tracking consumer healthcare names like Haleon alongside broader market conditions, the AI Screener offers a practical way to streamline research and surface actionable ideas.

Market Reaction and Investor Sentiment

The market responded sharply to the miss. Haleon's American Depositary Receipts (ADRs) fell roughly 14.7% in premarket trading following the announcement, reflecting investor disappointment over the guidance cut and the China headwind. The downward revision from 3%–5% organic growth to around 2.5% signaled that management's turnaround is taking longer than anticipated, particularly in pain relief and respiratory categories. While the additional £500 million buyback and reaffirmed profit outlook offered some support, sentiment was dominated by concerns about the durability of growth and the company's ability to return to its medium-term range. The absence of a near-term resolution in China further dampened confidence.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Haleon can stabilize growth in the fourth quarter and into 2027. Management pointed to a favorable start to the U.S. cold and flu season, with category growth in the high teens over the past four weeks, but cautioned that the season remains difficult to predict and that roughly 70% of the cold and flu business sits outside the U.S.

The China classification issue remains a key swing factor. With no clear path to resolution through 2027, Haleon is working to mitigate the impact by shifting its portfolio toward health food products and accelerating launches such as Benefiber in the fourth quarter. Investors should monitor how effectively these mitigations offset lost Centrum OTC sales.

Cost and margin execution will also be critical. The company continues to expect high-single-digit adjusted operating profit growth at constant currency, supported by gross margin strength and supply chain productivity. Sustaining that profit growth while reinvesting behind brands will be central to restoring confidence. Finally, any commentary on the medium-term 4%–6% growth ambition and progress in North America's pain relief turnaround will be closely scrutinized in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations